Related Experiment Videos
Vigabatrin: no microvacuoles in a human brain
B Pedersen1, K Højgaard, M Dam
1University Clinic of Neurology and Pathology, Hvidovre Hospital, Denmark.
Epilepsy Research
|January 1, 1987
Summary
Vigabatrin (gamma-vinyl-GABA) is an effective antiepileptic drug. A human autopsy study found no brain microvacuoles, suggesting this side effect may not occur in humans.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Vigabatrin (gamma-vinyl-GABA) is a recognized antiepileptic medication.
- Preclinical studies in rats and dogs indicated potential intramyelinic edema (microvacuoles) as a side effect.
- This finding has limited clinical investigations of vigabatrin.
Observation:
- An autopsy was performed on a 38-year-old female patient with astrocytoma.
- The patient received vigabatrin therapy for drug-resistant epilepsy over an extended period.
- Vigabatrin dosage was 80 mg/kg/day for >6 months, then 125 mg/kg/day for 2 months.
Findings:
- Microvacuoles, or intramyelinic edema, were not detected in the patient's brain.
- This observation contrasts with findings in rodent and canine models.
- Microvacuoles have not been previously observed in primate studies.
Implications:
- The absence of microvacuoles in this human case suggests potential species-specific toxicity.
- Further investigation into vigabatrin's safety profile in humans is warranted.
- This research supports continued evaluation of vigabatrin as a treatment for epilepsy.